Results 91 to 100 of about 4,196 (141)

COVID-19 Vaccination and Cardiovascular Events: A Systematic Review and Bayesian Multivariate Meta-Analysis of Preventive Benefits and Risks. [PDF]

Int J Prev Med
Karimi R, Norozirad M, Esmaeili F, Mansourian M, Marateb HR.   +4 more
europepmc   +1 more source

Impact of chronic cholecalciferol supplementation and vitamin D status on risk of post-vaccination SARS-CoV-2 breakthrough infection. [PDF]

Endocrine
di Filippo L, Bolamperti S, Campaniolo M, Gifuni L, Giustina A.   +4 more
europepmc   +1 more source

BNT162b2 2024-2025 Vaccine Effectiveness Against COVID-19 in Children Aged 6 Months-17 Years. [PDF]

J Pediatric Infect Dis Soc
Tartof SY, Ahi T, Frankland TB, Slezak JM, Zamparo JM, Ackerson BK, Puzniak L.   +6 more
europepmc   +1 more source

Does mRNA-based COVID-19 vaccination in the subacute phase lead to microstructural brain changes? A prospective pilot MRI study using T1 relaxometry. [PDF]

Sci Rep
Willems R, Cappelletti M, Schüre JR, Deichmann R, Hattingen E, Arendt CT.   +5 more
europepmc   +1 more source

Acute myocarditis and rhabdomyositis after coronavirus disease 2019 messenger RNA vaccination and intensive training: a case report. [PDF]

J Med Case Rep
Wu J, Szakos A, Bozoky B, Szekely L.
europepmc   +1 more source

Cytomegalovirus-Based Viral Vectors Elicit Robust Systemic and Tissue-Resident Immune Response Against SARS-CoV-2 Antigens. [PDF]

Eur J Immunol
Cokarić Brdovčak M, Materljan Franki J, Šustić M, Miklić K, Medved M, Gaćina L, Ružić T, Jonjić S, Brizić I, Krmpotić A.   +9 more
europepmc   +1 more source

Risk of New-Onset Myasthenia Gravis Following COVID-19 Infection and Vaccination: A Population-Based Case-Control Study. [PDF]

Eur J Neurol
Kab T, Pardo K, Hellmann MA, Lotan I, Friedman Y, Shochat T, Wilf-Yarkoni A.   +6 more
europepmc   +1 more source

Post coronavirus-disease-vaccination immune reconstitution inflammatory syndrome in tuberculosis treatment: a case report. [PDF]

J Med Case Rep
Mehta A, Pant A.
europepmc   +1 more source

Meningitis B vaccination. [PDF]

CMAJ
Rani S, Coletto S, Hasselback J.
europepmc   +1 more source

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12\u201317 Years \u2014 U.S. December 9, 2021\u2013February 20, 2022

What is already known about this topic? Adults aged 6518 years reported adverse reactions less frequently after receipt of a homologous Pfizer-BioNTech COVID-19 booster dose than after the second primary dose.What is added by this report?

core